Feldan Therapeutics

Oct 31, 2024 | newswire.ca | Feldan Therapeutics

, /CNW/ - Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, has announced its first patient being dosed in Phase 1/2a clinical study of Lead development candidate FLD-103; an intralesional injection intended to provide an alternative to surgery to patients diagnosed with basal cell carcinoma (BCC).

Sep 4, 2024 | newswire.ca | Feldan Therapeutics

, /CNW/ - Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, has announced the closure of a US$ 21 million Series B round co-led by Genesys Capital (Genesys) and Fonds de solidarité FTQ (Fonds). This Series B extension follows financing announced in June 2023 and which also includes participation from Investissement Québec, Amgen Ventures, GC Holdings, and other existing shareholders.

Jun 13, 2023 | fox8.com | Feldan Therapeutics

, /PRNewswire/ - Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.

Mar 13, 2023 | jofskin.org | Nancy Messier |Feldan Therapeutics |Quebec Canada |Frédéric Couture

Main Article Content Keywords Basal Cell Carcinoma, BCC, Skin Cancer, Keratinocyte Cancer, KC, intralesional, intralesional injection, intralesional therapy, BCC mouse model, Feldan shuttle, ASO, antisense oligonucleotide, inducible NBCCS-like mouse model, mouse model, Gli1, FLD103 Abstract Introduction: Patients with nevoid basal cell carcinoma syndrome (NBCCS), also termed Gorlin syndrome, develop numerous basal cell carcinomas (BCCs). Current treatment options include systemic hedgehog...